Suppr超能文献

纤溶酶原激活物抑制剂-1的结构-功能关系及其作为治疗剂的潜力。

Structure-function relationships of plasminogen activator inhibitor-1 and its potential as a therapeutic agent.

作者信息

Cale Jacqueline M, Lawrence Daniel A

机构信息

Department of Internal Medicine, Cardiovascular Research Center, University of Michigan, 1150 W Medical Center Dr, Ann Arbor, MI 48109, USA.

出版信息

Curr Drug Targets. 2007 Sep;8(9):971-81. doi: 10.2174/138945007781662337.

Abstract

Plasminogen activator inhibitor-1 (PAI-1) is the primary inhibitor of tissue-type and urokinase-type plasminogen activators (tPA and uPA, respectively). PAI-1 also interacts with non-proteinase targets such as vitronectin, heparin, and several endocytic receptors of the low-density lipoprotein-receptor family, including the low-density lipoprotein-receptor related protein (LRP) and the very low-density lipoprotein receptor (VLDLr). PAI-1 is a multifunctional protein that is not only a physiologic regulator of fibrinolysis and cell migration but is also associated with several acute and chronic pathologic conditions. PAI-1 is involved in the pathophysiology of renal, pulmonary, cardiovascular, and metabolic diseases, and in vitro experiments and animal studies have elucidated PAI-1's contribution to the physiology or pathology of some of these conditions. PAI-1 is normally present at low levels in plasma, but acute and chronic diseases are strongly associated with increased PAI-1 expression and release. At sites of vascular injury and inflammation, local PAI-1 levels are even higher, due to its concentration in extracellular matrix through association with vitronectin. Elevated local or systemic PAI-1 is not only a marker of disease; it can also exacerbate pathologic conditions. Thus, interventions that directly target PAI-1 may be useful for the treatment of a number of chronic and acute disorders. Typically, such interventional strategies would involve the identification of small molecule inhibitors of PAI-1, and several recent reviews have covered this topic. However, it may also be possible or even potentially advantageous, to exploit the diverse functional interactions of PAI-1 to create highly specific and targeted therapeutic agents based on the PAI-1 protein itself. To understand how PAI-1 could be developed as a therapeutic agent, it is first necessary to discuss its structural and functional characteristics in depth.

摘要

纤溶酶原激活物抑制剂-1(PAI-1)是组织型和尿激酶型纤溶酶原激活物(分别为tPA和uPA)的主要抑制剂。PAI-1还与非蛋白酶靶点相互作用,如玻连蛋白、肝素以及低密度脂蛋白受体家族的几种内吞受体,包括低密度脂蛋白受体相关蛋白(LRP)和极低密度脂蛋白受体(VLDLr)。PAI-1是一种多功能蛋白,不仅是纤维蛋白溶解和细胞迁移的生理调节因子,还与多种急性和慢性病理状况相关。PAI-1参与肾脏、肺部、心血管和代谢疾病的病理生理过程,体外实验和动物研究已阐明PAI-1对其中一些疾病的生理或病理过程的作用。PAI-1在血浆中通常以低水平存在,但急性和慢性疾病与PAI-1表达和释放增加密切相关。在血管损伤和炎症部位,由于其通过与玻连蛋白结合而集中在细胞外基质中,局部PAI-1水平甚至更高。局部或全身PAI-1升高不仅是疾病的标志物;它还会加重病理状况。因此,直接靶向PAI-1的干预措施可能对治疗多种慢性和急性疾病有用。通常,此类干预策略将涉及鉴定PAI-1的小分子抑制剂,最近的几篇综述已涵盖此主题。然而,利用PAI-

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验